AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01048905
Drug: L-Glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children \< 15 years of age.
Trial: NCT01911780
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching amlodipine capsule
Trial: NCT03436199
Drug: ADS-5102, 137 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT03436199
Drug: ADS-5102, 274 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT01910220
Drug: REGN1033 (SAR391786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00910455
Drug: SRX246
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of SRX246 capsule
Trial: NCT00910455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of placebo capsule
Trial: NCT02540395
Drug: 6-methyl prednisolone (Steroids) (for Group B)
RxNorm normalized name: 6-methyl citronellol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).~Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed.
Trial: NCT02540395
Drug: 6-methyl prednisolone (Steroids) (for Group A)
RxNorm normalized name: 6-methyl citronellol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).~Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day.
Trial: NCT03188887
Drug: corticotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 IV pulses steroids followed by oral steroids for 4 months
Trial: NCT00456235
Drug: Ciclosporine A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03004924
Drug: SHP640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill 1 drop of SHP640 (povidone-iodine \[PVPI\] 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Trial: NCT03029585
Drug: NanoPac® 100 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Trial: NCT03029585
Drug: NanoPac® 200 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Trial: NCT03029585
Drug: NanoPac® 300 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Trial: NCT03029585
Drug: NanoPac® 400 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Trial: NCT03029585
Drug: Standard of Care Intravenous Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Trial: NCT03004924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
Trial: NCT01581476
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg daily for a minimum period of 2 years
Trial: NCT01581476
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
Trial: NCT01581476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive statin placebo and ACEI placebo
Trial: NCT02148120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00903981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
Trial: NCT01420328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 6 weeks
Trial: NCT00864136
Drug: Conventional medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
Trial: NCT00864136
Drug: Conventional medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women using anti-fibrinolytic agent for treatment of menorrhagia
Trial: NCT00668746
Drug: Minocycline HCl microspheres
RxNorm normalized name: minocycline HCl microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
Trial: NCT03362294
Drug: GA Depot 40mg once monthly
RxNorm normalized name: methylPREDNISolone acetate 40 MG/ML [DEPO-Medrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
Trial: NCT04184622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00892970
Drug: Azithromycin ophthalmic solution, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
Trial: NCT00892970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
Trial: NCT01668498
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
Trial: NCT01668498
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
Trial: NCT01123005
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mCi, IV
Trial: NCT05686772
Drug: Dopamine partial agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antipsychotics (i.e., dopamine partial agonists vs dopamine antagonists)
Trial: NCT00538174
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, up to 14 days
Trial: NCT00856661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, single bolus over 1 to 2 minutes on 1st day
Trial: NCT01980615
Drug: Inhaled BGF (PT010) Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01980615
Drug: Inhaled BGF (PT010) Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01984801
Drug: 0.3% GSK1940029 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of the gel will be applied to individual patches by using a spatula
Trial: NCT01984801
Drug: 1% GSK1940029 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of the gel will be applied to individual patches by using a spatula
Trial: NCT01984801
Drug: 0.3%/1% vehicle gel only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of the gel will be applied to individual patches by using a spatula
Trial: NCT01121198
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02602002
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02602002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01768572
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dispensed according to local practice.
Trial: NCT00840242
Drug: Placebo gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-12 pieces per day, maximum 24 daily
Trial: NCT00840242
Drug: Placebo inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-12 cartridges per day, maximum 12 daily
Trial: NCT01279447
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10cc, single dose, US guided injection
Trial: NCT03888183
Drug: salt solution without 0.15% HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received AIM Artificial Tears (4 to 8 times per day) with 12 weeks
Trial: NCT03888183
Drug: preservative-free 0.15% HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received Per-Young Eye Drops (4 to 8 times per day) with 12 weeks
Trial: NCT01906073
Drug: intranasal fentanyl spray
RxNorm normalized name: fentanyl Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03248076
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1γ/Kg fentanyl
Trial: NCT00889863
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
Trial: NCT03186482
Drug: Descovy® (TAF/FTC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25/200 mg once daily for 28 days (DAYS 1-28).
Trial: NCT03186482
Drug: Viread® (TDF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 245 mg once daily for 28 days (DAYS 57-84).
Trial: NCT03186482
Drug: Rifadin® (Rifampicin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg once daily for 28 days (DAYS 29-56).
Trial: NCT00346801
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
Trial: NCT00346801
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
Trial: NCT03393702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.~2. Patients after surgery receive identical placebo capsules 2 times per day.
Trial: NCT03192644
Drug: epidoxorubicin and cisplatin and lipiodol
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epidoxorubicin and cisplatin and lipiodol
Trial: NCT00550550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual tablet, once daily
Trial: NCT02951806
Drug: (R) Rapid spinal fentanyl injection
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
Trial: NCT02951806
Drug: (S) Slow spinal fentanyl injection
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
Trial: NCT04379310
Drug: ACE Inhibitors and Calcium Channel Blockers
RxNorm normalized name: ACE inhibitors and calcium channel blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effect of drugs on patients with covid-19 pneumonia
Trial: NCT00257205
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-675,206 15 mg/kg IV Q 90 days x 4
Trial: NCT03345628
Drug: Sedatives
RxNorm normalized name: SEDATIVES/HYPONTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sedated group received sedative drugs to tolerated intubation and ventilation
Trial: NCT00803205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to ataluren will be provided.
Trial: NCT04296851
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
Trial: NCT03611985
Drug: Epidiferphane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months.
Trial: NCT03611985
Drug: Taxane Chemotherapy
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
Trial: NCT03772899
Drug: Fecal Microbial Transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017.
Trial: NCT00818519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert tablet
Trial: NCT03747575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC placebo
Trial: NCT01292005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
Trial: NCT00498797
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03867123
Drug: LAM561
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
Trial: NCT01911819
Drug: Equimatrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
Trial: NCT01911819
Drug: Bio-oss
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
Trial: NCT03370588
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Saline infusion during same time period.
Trial: NCT04008004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EDP-514
Trial: NCT02225288
Drug: E2022
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
Trial: NCT01071317
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg PO bid prn headache
Trial: NCT00545909
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 6 months (+ feedback)
Trial: NCT00545909
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 6 months (- feedback)
Trial: NCT04952207
Drug: Direct-acting antiviral agents
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
Trial: NCT01897571
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.
Trial: NCT01697956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
Trial: NCT00939211
Drug: AZD9164
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for inhalation through nebulization, single dose
Trial: NCT00939211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00966706
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given systemically
Trial: NCT00874393
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine
Trial: NCT00874393
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone
Trial: NCT00874393
Drug: Infusion Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose (D5W)
Trial: NCT00603278
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW685698X
Trial: NCT00603278
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01779089
Drug: Minocycline 100 mg po bid for 6 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg po bid or placebo for 6 months
Trial: NCT01779089
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01428622
Drug: BI54903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethanolic solution
Trial: NCT01786915
Drug: Bendavia 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01786915
Drug: Bendavia 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01786915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00959634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose administered twice daily on Study Days 1-10
Trial: NCT03258034
Drug: SPA
RxNorm normalized name: TSPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
Trial: NCT06212596
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
Trial: NCT03715634
Drug: INDV-6200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo